A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.
Rutgeerts PJ; Fedorak RN; Hommes DW; Sturm A; Baumgart DC; Bressler B; Schreiber S; Mansfield JC; Williams M; Tang M; Visich J; Wei X; Keir M; Luca D; Danilenko D; Egen J; O'Byrne S; Gut, 2013, vol. 62, issue 8, p 1122, ISSN 14683288. ISBN 14683288.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef